PepGen climbs after $125 mln equity raise for muscle disease drug

By Reuters News

** Shares of PepGen PEPG.O up 6.5% at $5.60 premarket on Thurs after $125 mln follow-on priced

** PEPG late Weds sold 25 mln shares at $5

** On Tues, PEPG's stock surged 93% to $4.61, an over seven-month high, after stronger-than-expected mid-stage trial results for its experimental drug, PGN-EDODM1, for myotonic dystrophy type 1 (DM1)

** Stock closed up ~14% at $5.26 on Weds

** Co to use net offering proceeds to fund clinical development of PGN-EDODM1, and for working capital and other general purposes

** Leerink, Stifel and Guggenheim are joint bookrunners; Oppenheimer is a passive bookrunner

** Boston, Massachusetts-based PEPG has ~69.26 mln shares outstanding

** Through Weds, stock down 19% YTD

** 7 of 8 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $11, per LSEG data

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk